HEPATITIS B SURVEILLANCE PROTOCOL

Public Health Action

1. Educate providers about appropriate use of the hepatitis B vaccine, especially in newborns and adolescents.

2. Educate the general public about hepatitis B risk factors, hepatitis B vaccine, and prevention of hepatitis B transmission.

3. Educate health care providers and laboratories to report IgM antibody to hepatitis B core antigen (anti-HBc) or hepatitis B surface antigen (HBsAg) positive patients to the local health department and the HIV/AIDS/STD Program at the West Virginia Bureau for Public Health (WVBPH) within 24 hours.

4. Within 24 hours of receiving a report of a HBsAg or HBcAb IgM positive patient the local health department will perform the following responsibilities:
   a. Conduct a record search to determine if this patient was previously investigated.
   b. Contact the physician to determine if the patient meets the case definition for acute hepatitis B.
      The following questions will assist in determining the patient’s status:
      i. Confirm patient’s demographics. e.g. address, phone number, etc.
      ii. Reason for testing?
      iii. Is the patient symptomatic? e.g. jaundice, nausea, vomiting, fatigue, dark urine, clay colored stool, etc.
      iv. Date of onset of illness?
      v. Is the patient pregnant? If yes, ask when is the EDD (estimated date of delivery) and notify the Perinatal Hepatitis B Coordinator at the Immunization Program immediately (1-800-642-3634).
      vi. Are there any other lab tests? e.g. hepatitis A & C, liver enzymes, bilirubin
      vii. Does the patient have a history of IV drug abuse and/or alcohol abuse?
      viii. Does the patient have a hepatitis B vaccine history?
      ▪ If yes, obtain the dates of vaccination, number of doses, manufacturer name and vaccine lot number
      ix. Did the physician notify the patient of the positive lab report?
      x. If the investigation warrants talking to the patient, inform the physician that you will be notifying the patient.
   c. If investigation reveals acute status, interview patient to collect public health and contact information related to the case. e.g. risk factors for disease, sexual partners, household and/or injection drug user (IDU) contacts and their locating information, etc.
   d. Provide partner notification to IDU contacts within 7 days and sexual and household contacts within 14 days of positive test. Follow up on the contacts as necessary to assure that they receive education on hepatitis B transmission/prevention, Hepatitis B Immune Globulin (HBIG) (as necessary) and vaccine.
e. If the patient meets the case definition for **acute hepatitis B infection**, enter data into West Virginia Electronic Disease Surveillance System (WVEDSS) which includes a reportable disease case report card and the CDC Viral Hepatitis Case Report form; include all laboratory studies (hepatitis A virus immunoglobulin M (HAVIgM), alanine transferase (ALT or serum glutamate pyruvate transaminase (SGPT), HBsAg, HBcAb IgM, and hepatitis C testing results, if available), and submit all data for State Review. *Until WVEDSS is functional, send a paper copy and all appropriate laboratory studies to the West Virginia HIV/AIDS/STD program, as well as submitting it electronically.*

f. If patient **does not** meet the clinical definition for acute hepatitis B infection but is HBsAg positive or HBeAg positive, provide:
   
i. education on hepatitis B transmission/prevention
   ii. partner notification to IDU contacts within 7 days and sexual and household contacts within 14 days of positive tests,
   iii. follow up on the contacts as necessary to assure that they received education on hepatitis B transmission / prevention, HBIG (as necessary) and hepatitis B vaccine
   iv. enter data into WVEDSS including labs and submit for State Review. *Until WVEDSS is functional, send a paper copy and all appropriate laboratory studies to the West Virginia HIV/AIDS/STD program, as well as submitting it electronically.*

g. If investigation reveals **chronic status**, (Hepatitis B surface antigen [HBsAg] positive, total anti-HBc positive [if done] and IgM anti-HBc negative, OR HBsAg positive two times at least 6 months apart) provide:
   
i. education on hepatitis B transmission/prevention
   ii. partner notification to IDU contacts within 7 days and sexual and household contacts within 14 days of positive test,
   iii. follow up on the contacts as necessary to assure that they received education on hepatitis B transmission / prevention, HBIG (as necessary) and hepatitis B vaccine
   iv. enter data into WVEDSS including labs and submit for State Review. *Until WVEDSS is functional, send a paper copy and all appropriate laboratory studies to the West Virginia HIV/AIDS/STD program, as well as submitting it electronically.*

The Disease Intervention Specialist (DIS) will perform the following responsibilities on all cases that require patient tracing, partner notification and follow-up as requested and/or assigned by the Local Health Department and or the HIV/AIDS and STD Program:

a. Interview the patient for all contacts (sexual partners, household and IDU)
b. Provide partner notification to IDU contacts within 7 days and sexual and household contacts within 14 days of positive test,
c. Complete Interview Record (73.54) and Field Record (2936) as necessary and submit to HIV/AIDS/STD Program,
d. Enter data into WVEDSS,
e. Follow up with the contacts as necessary to assure that they received education on hepatitis B prevention / transmission, HBIG (as necessary) and hepatitis B vaccine.

**If you have any questions or additional assistance is needed in interpreting hepatitis B lab reports, please call the State Hepatitis B Epidemiologist at 1-800-642-8244.**

*West Virginia Department of Health and Human Resources, Bureau for Public Health, September 2005, Page 2 of 26*
5. The local health department will assure that all patients who meet the case definition for acute hepatitis B infection or are HBsAg and/or HBcAb IgM positive receive education on hepatitis B prevention/transmission. If a contact receives HBIG and/or hepatitis B vaccine, the local health department will complete the Hepatitis B Vaccine/HBIG Tracking form (see attachment) and submit it to the HIV/AIDS/STD Program.

6. Investigate forward (to prevent disease in contacts):
   a. Identify all sexual contacts and determine the date of last contact with the source patient. If the last contact with the patient is within 14 days, and the vaccine or immune status is not known:
      1. Submit a blood sample from the contact(s) to the West Virginia Office of Laboratory Services (OLS) for a hepatitis B screen.
         ➢ If the contact is pregnant, indicate the number of weeks on the Serology Laboratory Hepatitis Requisition Form (see attachment).
      2. Administer hepatitis B immunoglobulin (HBIG) and the first dose of hepatitis B vaccine to the contact(s). The State Health Department may provide both HBIG and hepatitis B vaccine for contacts of acute hepatitis B patients.
      3. If hepatitis serologies are positive, stop the vaccination series and refer the patient for medical care. If serologies are negative, complete the full immunization series.
      4. Complete the tracking form and submit it to the HIV/AIDS/STD Program.
   b. Identify all needle sharing contacts and determine the last contact with the source patient. If the date of the last needle sharing event with the source patient is within seven days, and vaccine and immune status are not known:
      1. Submit a blood sample from the contact(s) to the OLS for a hepatitis B screen.
         ➢ If the contact is pregnant, indicate the number of weeks on the Serology Laboratory Hepatitis Requisition Form (see attachment).
      2. Administer HBIG as well as the first dose of hepatitis B vaccine to the contact(s). The State Health Department may provide both HBIG and hepatitis B vaccine for contacts of acute hepatitis B patients.
      3. If hepatitis serologies are positive, stop the vaccination series and refer the patient for medical care. If serologies are negative, complete the full immunization series.
      4. Complete the tracking form and submit it to the HIV/AIDS/STD Program.
      5. HBIG must be administered within a week after the last needle sharing event with the source patient.
   c. Identify all household contacts and determine if they have had any blood exposure to the source patient (e.g. shared razor, etc.). If a blood exposure is identified within 14 days:
      1. Draw a blood sample from the contact(s) and send it to the OLS for a hepatitis B screen.
         ➢ If the contact is pregnant, indicate the number of weeks on the Serology Laboratory Hepatitis Requisition Form (see attachment).
      2. Administer HBIG and the first dose of hepatitis B vaccine to the contact(s). The State Health Department may provide both HBIG and hepatitis B vaccine for contacts of acute hepatitis B patients.
3 If hepatitis serologies are positive, stop the vaccination series and refer the patient for medical care. If serologies are negative, complete the full immunization series.

4 Complete the tracking form and submit it to the HIV/AIDS/STD Program.

5 If the household contact is an infant and the mother or primary care giver has acute hepatitis B infection, administer HBIG and hepatitis B vaccine to the infant immediately. Complete the series for the infant. For partially or fully immunized infants, contact Infectious Disease Epidemiology Program (IDEP) for an individualized recommendation.

6 If the source patient is or becomes a hepatitis B carrier, all household contacts should receive the hepatitis B vaccine series.

d. If the index patient is pregnant, the local health department should assure that all of the following pre-natal and post natal activities occur:

1 Prenatal:
   a. Notify the WV Perinatal Hepatitis B Coordinator of the Hepatitis B surface antigen positive, pregnant mother.
   b. Educate the mother regarding hepatitis B disease.
   c. Educate the mother of the infant's need for HBIG and the first dose of hepatitis B vaccine within 12 hours of birth.
   d. Notify the birthing facility of patient and ensure the HBIG and a dose of hepatitis B vaccine are available. If the hospital or health care provider is unable to provide HBIG and the first dose of hepatitis B vaccine for the patient due to financial circumstances (medically indigent clients), inform:
      (i) The WV Perinatal Hepatitis B Coordinator at 1-800-642-3634 or 304-558-6445 OR
      (ii) HIV/AIDS and STD Program at 1-800-642-8244 or 304-558-2195 OR
      (iii) After hours, contact IDEP on call at 1-800-423-1271 or 304-558-5358.

      HBIG may be supplied by the state health department after consultation with the infectious disease epidemiologist.

   e. Assure physician’s orders are written to administer HBIG and the first dose of hepatitis B vaccine within 12 hours of birth.
   f. Communicate with the birthing facilities infectious disease personnel to ensure notification of:
      (i) infant’s date of birth
      (ii) date & time of HBIG administration
      (iii) date & time of hepatitis B vaccination
      (iv) pediatrician identification.

2 Post Natal:
   a. Notify, within 3 days of birth, the WV Perinatal Hepatitis B Coordinator of birth and post natal care status. (This will ensure the administration of HBIG within 7 days.)
      (i) WV Perinatal Hepatitis B Coordinator 1-800-642-3634 or 304-558-6445.
      (ii) After hours or if unable to contact WV Perinatal Hepatitis B Coordinator, call IDEP at 1-800-423-1271 or 304-558-5358.
b. Communicate with the physician to ensure that the following occur:
   ➢ the infant receives the second and third doses of hepatitis B vaccine on schedule and the immunization record is reported to the West Virginia Statewide Immunization Information System (WVSIIIS).
   ➢ serological testing is completed at three to nine months after the third dose of hepatitis B vaccine and at 9 to 15 months of age.
   ➢ serological testing includes both HBsAg and HBsAb (check both “perinatal” and “post vaccination” on the form for OLS).

c. Lab interpretations:
   ➢ If the baby is HBsAg positive, refer for medical evaluation.
   ➢ If HBsAg is negative and anti-HBs antibody is positive, children are considered to be protected.
   ➢ If HBsAb and HBsAg are negative, repeat the series and repeat serologic testing.

d. Forward clinical information to the Immunization Program Perinatal Hepatitis B Coordinator upon receipt.

e. **Report to WVEDSS if the patient meets the case definition for Perinatal hepatitis B infection.**
   ➢ Enter data into WVEDSS which includes a reportable disease case report card and the CDC Viral Hepatitis Case Report form; include all laboratory studies available (hepatitis A virus immunoglobulin M (HAVIgM), alanine transferase (ALT), HBsAg, HBCAb IgM, and hepatitis C testing results)
   ➢ Submit all data for State Review.
      o Until WVEDSS is functional, send a paper copy and all appropriate laboratory studies to the West Virginia Immunization Program Perinatal Hepatitis B Coordinator, as well as submitting it electronically.

7. For cases with **acute hepatitis B**, investigate backward, as follows:
   a. Using a calendar, determine the incubation period for the case. The incubation period is six weeks to six months prior to the date of onset.
   b. Collect information on all possible risk factors during the incubation period, and record it on the reportable disease case report card and the CDC Viral Hepatitis Case Report form. Discuss any unusual risk factors or clustering of risk factors with the West Virginia HIV/AIDS and STD Program. Risk factors and possible risk factors include:
      1. Contact with a person with suspected or confirmed HBV infection;
      2. Employment involving contact with human blood;
      3. Receipt of blood transfusion or blood products;
      4. Dialysis or kidney transplant patient;
      5. Injecting drug use;
      6. Number of different male sexual partners;
      7. Number of different female sexual partners;
      8. Hospitalization and/or surgery;
      9. Intravenous infusions or injections received in outpatient settings;
      10. Residence in a long term care facility (e.g. nursing home);
11 Dental work/oral surgery;
12 Accupuncture/tattooing/body piercing; and
13 Puncture with a needle or other object contaminated with blood.
14 Incarceration.

c. Investigate vaccination history and record as part of the investigation, including:
1 Number of vaccine doses, dates(s) of vaccination, and post-vaccination test results, if available, and
2 Missed opportunities for hepatitis B vaccination, including:
   a. Household or sex contact with an HBV-infected person;
   b. Ever in a correctional facility;
   c. Ever treated for a sexually transmitted disease; or
   d. Ever in treatment for injecting drug use.

8. For patients with chronic hepatitis B, record all action taken on the reportable disease case report card and submit it with copies of all lab tests to the HIV/AIDS/STD Program.

9. For patients with acute hepatitis B, record all action taken on the reportable disease case report card, and submit it with copies of all lab tests and the completed CDC supplemental form to the HIV/AIDS/STD Program.

10. Refer for medical evaluation
   a. Persons with acute hepatitis B should be evaluated for development of chronic infection
   b. Detection of HBsAg >6 months after illness onset indicates the presence of chronic infection.
   c. Evaluate for chronic liver disease, eligibility for treatment.

**Disease Prevention Objectives**

1. Reduce the incidence of hepatitis B by:
   a. Assuring full hepatitis B immunization of all infants.
   b. Assuring “catch-up” hepatitis B immunization of all adolescents at the adolescent visit.
   c. Assuring full hepatitis B immunization of high-risk individuals to include:
      i. Sexually active adolescents and adults (including adolescents in STD clinics);
      ii. Household contacts and sexual partners of HBV carriers;
      iii. Health care personnel and those who have occupational exposure to blood;
      iv. Residents and staff of institutions for the developmentally disabled;
      v. Hemodialysis patients;
      vi. Recipients of certain blood products;
      vii. International travelers;
      viii. Injection drug users; and
      ix. Inmates in long term correctional facilities.

2. Reduce the incidence of hepatitis B through community education and programs to prevent drug use and sharing of needles.

3. Prevent nosocomial transmission of hepatitis B through effective infection control measures.
4. Prevent transmission of hepatitis B through screening of blood and organ donors.

**Disease Control Objectives**

1. Identify and investigate community-based and nosocomial outbreaks of hepatitis B in a timely fashion so that appropriate control measures can be applied.

2. Reduce transmission from persons with hepatitis B infection including:
   a. Perinatal transmission; and
   b. Transmission to household, sexual, and drug-using partners.

**Surveillance Objectives**

1. Determine the incidence of acute hepatitis B in West Virginia.

2. Determine the risk factors associated with acute and chronic hepatitis B in West Virginia.

3. Determine the demographic characteristics of persons with acute and chronic hepatitis B.

4. Distinguish between failure to immunize (preventable cases) versus failure of vaccine (non-preventable cases) among the reason(s) for continued occurrence of hepatitis B.

5. Detect outbreaks, clusters, or unusual patterns of transmission of hepatitis B.

6. Estimate the annual number of newly diagnosed chronic cases of hepatitis B.

**Public Health Significance**

Hepatitis B is a vaccine preventable disease. When the vaccine was first introduced in 1982, it was recommended for high-risk groups (e.g. men who have sex with men, persons with multiple sexual partners or a history of a sexually transmitted disease, injection drug users, health care workers or persons with occupational exposure to blood, etc.). However, the number of cases of hepatitis B continued to increase after the vaccine was introduced. In 1991, universal infant immunization was instituted, followed by a recommendation for catch-up vaccination of adolescents in 1996. At this time, the incidence of hepatitis B is declining.

Chronic hepatitis B virus infection is associated with the development of hepatocellular carcinoma. In Southeast Asia, HBV infection is endemic and hepatocellular carcinoma is a common cause of cancer death. After launching a nationwide vaccination program in Taiwan to control hepatitis B, the HBsAg carrier rate in children declined from about 10% to 1% within 10 years of implementation. Concurrently, the average annual incidence of hepatocellular carcinoma per 100,000 children six to 14 years of age declined from 0.70 between 1981 and 1986; to 0.57 between 1986 and 1990; and to 0.36 between 1990 and 1994. The incidence of hepatocellular carcinoma in children six to nine years of age declined from 0.52 per 100,000 for those born between 1974 and 1984 to 0.13 per 100,000 for those born between 1984 and 1986. This was the first demonstration that
mass vaccination could reduce the incidence of a specific cancer in humans.

According to the CDC, one of 20 persons in the U.S. has been infected with hepatitis B virus during their lifetime (about 12.5 million); one of 200 persons has chronic (lifelong) infection with hepatitis B virus (about 1.25 million); and 4,000 to 5,000 persons die each year from hepatitis B-related chronic liver disease (cirrhosis, liver cancer).

In the United States, children become infected with HBV through a variety of means. The risk of perinatal HBV infection among infants born to HBV-infected mothers ranges from 10% to 85% depending on each mother’s hepatitis B e antigen (HBeAg) status. Infants who become infected by perinatal transmission have a 90% risk of chronic infection, and up to 25% will die of chronic liver disease as adults. Even when not infected during the perinatal period, children of HBV-infected mothers remain at high risk of acquiring chronic HBV infection by person-to-person horizontal transmission during the first five years of life. More than 90% of these infections can be prevented if HBsAg positive mothers are identified so that their infants can receive hepatitis B vaccine and hepatitis B immune globulin (HBIG) soon after birth.

**Clinical Description**

**Signs and Symptoms of Acute Disease**

Typical symptoms include tiredness, headache, loss of appetite, nausea, vomiting, fever, and chills with onset three to 10 days prior to jaundice. Right upper quadrant pain is common. Urine may become dark, and stools may become clay-colored. The hallmark of the disease is jaundice (yellow color of the skin and sclera). Infants and children are usually asymptomatic, and an estimated 50% of adults with acute HBV are asymptomatic.

Fulminant hepatitis occurs in very few patients and is usually fatal. Duration of illness is usually several weeks, with symptoms occasionally persisting beyond three to four months.

**Signs and Symptoms of Chronic Infection**

Ninety to ninety-four percent of adults with acute HBV will develop protective antibodies within six months of the infection. A small proportion (6-10%) of adult patients with acute HBV will develop chronic infection. Most persons with chronic infection will not have symptoms but will continue to be infectious. Complications of chronic hepatitis B infection may include cirrhosis and hepatocellular carcinoma.

**Etiologic Agent**

HBV is a small double-stranded DNA virus. The outer protein coat contains the hepatitis B surface antigen.

**Reservoir**

This virus is found only in humans. Chimpanzees are susceptible, but an animal reservoir in nature has not been identified.
Mode of Transmission

In the United States, the most common risk factor for transmission of HBV is sexual contact with an infected person; however, the greatest risk for development of chronic infection is through perinatal transmission. The hepatitis B virus is also transmitted by parenteral or mucosal exposure to body fluids containing the virus. Breaks in the skin, such as scratches, abrasions, and burns, may serve as routes for the virus to enter the body.

The virus can be found in blood, body fluids (e.g. wound exudates), semen, cervical fluid, and saliva of persons who are HBsAg positive. Blood and serous fluids have the highest concentration of virus, and saliva the lowest.

Person-to-person transmission may occur in household settings. In these settings, non-sexual transmission occurs predominantly from child to child, and young children are at highest risk. The precise mechanism for child to child transmission is not known; however, frequent personal contact between non-intact skin or mucous membranes with blood containing secretions or, perhaps, saliva, are possible mechanisms. Transmission from sharing inanimate objects may also occur because HBV can survive at ambient temperature for one week or longer.

Incubation Period

The incubation period is usually 45 to 180 days, with an average of 60 to 90 days. Time to detection of HBsAg can be as short as two weeks or as long as six to nine months, depending on inoculum, host factors, and other variables.

Infectious Period

All persons who are HBsAg positive are potentially infectious. The presence of HBeAg is associated with a very high level of infectivity.

Case Definition for Acute Hepatitis B

Clinical Description

An acute illness with: a) discrete onset of symptoms, and b) jaundice or elevated serum aminotransferase levels.

Laboratory Criteria for Diagnosis

- IgM antibody to hepatitis B core antigen (anti-HBc) positive or hepatitis B surface antigen (HbsAg) positive.
- IgM anti-HAV negative (if done).

Case Classification

Confirmed: a case that meets the clinical case definition and is laboratory confirmed.

Comments

Persons who have chronic hepatitis or persons identified as HBsAg positive should not be reported as having acute viral hepatitis unless they have evidence of an acute illness compatible with viral hepatitis (with the exception of perinatal hepatitis B infection).
Delta hepatitis is not a nationally notifiable disease.

**Case Definition for Perinatal HBV Infection**

*Clinical Description*

Perinatal HBV infection in a newborn can range from asymptomatic to fulminant hepatitis.

*Laboratory Criterion for Diagnosis*

Hepatitis B surface antigen (HBsAg) positive.

*Case Classification*

Confirmed: HBsAg positivity in any infant >1 month old to 24 months old who was born in the United States or in U.S. territories to an HBsAg-positive mother.

**Case Definition for Chronic Hepatitis B**

*Clinical description*

Persons with chronic hepatitis B virus (HBV) infection may be asymptomatic. They may have no evidence of liver disease or may have a spectrum of disease ranging from chronic hepatitis to cirrhosis or liver cancer.

*Laboratory criteria*

Hepatitis B surface antigen (HBsAg) positive, total anti-HBc positive (if done) and IgM anti-HBc negative, OR
HBsAg positive two times at least 6 months apart

*Case Classification*

Confirmed. A case that is laboratory confirmed.

*Note: This case definition was approved by CSTE in June 2002.*

*Comment:*

HBsAg positive test results by enzyme immunoassay (EIA) that are not supported by positive test results for total anti-HBc or IgM anti-HBc should be confirmed by an additional more specific assay (e.g. neutralization assay)
Laboratory Testing

The table below is adapted from the Centers for Disease Control and Prevention. It is a quick guide to interpretation of hepatitis B serologies. It is important to recognize that unusual or inconsistent serologies are frequently reported. If in doubt about the patient diagnosis based on the laboratory results, it is often useful to repeat the testing.

<table>
<thead>
<tr>
<th>Tests</th>
<th>Results</th>
<th>Interpretations</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg anti-HBc anti-HBs</td>
<td>negative negative negative</td>
<td>Susceptible</td>
</tr>
<tr>
<td>HBsAg anti-HBc anti-HBs</td>
<td>negative positive positive</td>
<td>Immune due to natural infection</td>
</tr>
<tr>
<td>HBsAg anti-HBc anti-HBs</td>
<td>negative negative positive</td>
<td>Immune due to hepatitis B vaccination</td>
</tr>
<tr>
<td>HBsAg anti-HBc IgM anti-HBc</td>
<td>positive positive negative</td>
<td>Acutely infected</td>
</tr>
<tr>
<td>HBsAg anti-HBc IgM anti-HBc</td>
<td>positive positive negative</td>
<td>Chronically infected</td>
</tr>
<tr>
<td>HBsAg anti-HBc IgM anti-HBc</td>
<td>negative positive negative</td>
<td>* Four interpretations possible</td>
</tr>
</tbody>
</table>

* Four Interpretations

1. May be recovering from acute HBV infection.
2. May be distantly immune, but the test may not be sensitive enough to detect a very low level of anti-HBs in serum.
3. May be susceptible with a false positive anti-HBc.
4. May be chronically infected and have an undetectable level of HBsAg present in the serum.

Definitions

- **Hepatitis B Surface Antigen (HBsAg):** A serologic marker on the surface of HBV. It can be detected in high levels in serum during acute or chronic hepatitis. The presence of HBsAg indicates that the person is infections. The body normally produces antibodies to HBsAg as part of the normal immune response to infection.

- **Hepatitis B Surface Antibody (anti-HBs):** The presence of anti-HBs is generally interpreted as indicating recovery and immunity from HBV infection. Anti-HBs also develops in a person who has been successfully vaccinated against hepatitis B.

- **Total Hepatitis B Core Antibody (anti-HBc):** Appears at the onset of symptoms in acute hepatitis B and persists for life. The presence of anti-HBc indicates previous or ongoing infection with hepatitis B virus (HBV) in an undefined time frame.

- **IgM Antibody to Hepatitis B Core Antigen (IgM anti-HBc):** This antibody appears during acute or recent HBV infection and is present for about 6 months.
Antibody to Hepatitis e Antigen (HBeAg): This is a marker of a high degree of HBV infectivity, and it correlates with a high level of HBV replication. It is primarily used to help determine the clinical management of patients with chronic HBV infection.

Antibody to HBe: This marker may be present in an infected or immune person. In persons with chronic HBV infection, its presence suggest a low viral titer and a low degree of infectivity.

Sources:
CDC Viral Hepatitis B Information
http://www.cdc.gov/ncidod/diseases/hepatitis/b/Bserology.htm

Immunization Action Coalition
http://www.immunize.org/catg.d/p2021b.htm

To send specimens to the OLS, collect the blood in a red top tube or a red and gray striped tube. Complete the Serology Laboratory Hepatitis Requisition Form (see attachment and/or OLS Serology website) and enclose it with the specimen. OLS offers three choices for testing:

- “Screen” will give HBsAg, Hbc Ab total. Other tests will be run if either or both of the screen markers are positive. Other markers possible are: IgM to Hbc, antiHBsAg, confirmation of HBsAg.
- “Postvaccine” will give anti-HBsAg or antibody to HBsAg.

To get HBsAg and anti-HBsAg, check Hepatitis B Virus "Screen” and “Post Vaccine."

OLS Serology website http://www.wvdhhr.org/labservices/labs/serology/index.cfm

Preventive Interventions

Hepatitis B vaccine is a very safe and effective vaccine for prevention of hepatitis B, and it is recommended for all babies, for adolescents who have not already had the vaccine, and for people who are at risk for hepatitis B:

- Babies who are born to a mother who is HBsAg positive;
- People who have a job that involves contact with blood and blood products;
- Injection drug users;
- Sexually active persons who have had more than one partner in the last six months or who have a sexually transmitted disease;
- Sexually active men who have sex with men;
- Household contacts and sexual partners of persons who are chronically HBsAg-positive;
- Residents and staff of institutions for developmentally disabled persons;
- Staff of nonresidential child care and school programs for developmentally disabled persons if the program is attended by a known HBsAg-positive person;
- Patients undergoing hemodialysis;
- Patients with bleeding disorders who receive clotting factor concentrates;
- Members of households with adoptees who are HBsAg-positive;
• International travelers to areas in which HBV infection is of high or intermediate endemicity;
• Inmates of juvenile detention and other correctional facilities.

**Treatment**

Patients should check with their doctor about treatment for chronic hepatitis B. No specific therapy for acute HBV infection is available. In chronically infected adults, interferon alpha has been demonstrated to induce a long-term remission in 25% to 40% of treated patients. The drug has been less effective for chronic infections acquired during early childhood. Lamivudine is also licensed for treatment of chronic HBV infection in adults, but no data are available for use in children.

**Surveillance Indicators**

• The proportion of acute cases with complete risk factor information.
• The proportion of acute cases with complete demographic data.
• The proportion of pregnant mothers for whom hepatitis B surface antigen status is known.
• The proportion of cases born to an HBsAg positive mothers that received the first hepatitis B vaccine dose <12 hours after birth.
• The proportion of cases that received the third hepatitis B vaccine dose <8 months after birth.
• The proportion of cases that received HBIG <12 hours after birth.
• The proportion of cases that received ≥ 3 hepatitis B vaccine doses.
• The proportion of infants born to HBsAg positive mothers who have blood drawn for anti-HBsAg and HBsAg.
• The number of household, sexual contact, and needle sharing contacts identified per case.
• The proportion of contacts of acute and previously unreported chronic cases that have complete information on the hepatitis B immunization status or missed opportunities.
West Virginia Department of Health and Human Resources
Information for the Public on Hepatitis B

What is hepatitis B?

Hepatitis B is a serious disease of the liver and is caused by a virus.

How is hepatitis B spread?

Hepatitis B is spread by having sex or sharing needles with a person who has the virus. It may also be spread within households if razors, toothbrushes, or other items are shared. A baby can get hepatitis B from the mother during birth if the mother is infected. Approximately 25% of all persons with hepatitis B have no known risk factors for infection.

How can hepatitis B be prevented?

There is a very safe and effective vaccine. It is recommended for all babies, for adolescents who have not already had the vaccine, and for people who are at risk for hepatitis B.

Who is at risk for hepatitis B?

One out of every 20 people will get hepatitis B some time in their life. Your risk is higher if you:

- are born to a mother who has the hepatitis B virus;
- have a job that involves contact with blood;
- live in the same house with someone who has lifelong hepatitis B infection;
- have sex with a person who has hepatitis B;
- have sex with more than one person;
- are a man and have sex with a man;
- shoot drugs;
- have hemophilia;
- are a patient or work in a home for the developmentally disabled; or
- have parents born in Southeast Asia, Africa, the Amazon Basin in South America, the Pacific Islands, or the Middle East.

What are the symptoms of hepatitis B?

Some people do not have symptoms. It takes between six weeks and six months to get sick after you contact the virus. If you have symptoms, they might be:

- yellowing of the skin and eyes;
- loss of appetite;
- nausea or vomiting;
- fever;
• stomach pain;
• pain in the joints;
• a very, very, tired feeling; or
• dark urine.

**How can I know if I have hepatitis B?**

A blood test for HBV can tell if a person has ever been infected.

**Do people usually recover from hepatitis B?**

Most adults (90%) recover from hepatitis B after several months. They clear the infection from their bodies and become immune. People who are immune will not get hepatitis B again and they cannot pass hepatitis B to others.

**Who is a carrier of hepatitis B?**

About 10% of adults and most children under the age of five infected with hepatitis B are unable to clear the infection from their bodies. These people no longer have symptoms but still carry the virus in their body and can infect others. About one million people in the U.S. carry hepatitis B.

**Is there any treatment for hepatitis B?**

Some people who are carriers have benefited from treatment with interferon. Talk to your doctor about this.

**If I am pregnant, should I worry about hepatitis B?**

Pregnant women who are infected with hepatitis B can spread the disease to their babies. Many of these babies will develop lifelong hepatitis B infection if they don’t get medicine and vaccine shortly after birth.

**If infected, what should I do to protect others?**

- Do not share a toothbrush, razor, or other items that could come in contact with blood.
- Cover open sores or other breaks in your skin.
- Do not donate blood, plasma, body organs, or sperm.
- Follow the “safer sex” practices by having only one sex partner and using latex condoms correctly every time you have sex.
- Your sex partner should get hepatitis B vaccine.
- If you are a carrier of hepatitis B, all the people who live with you should get the vaccine.
- If you are injecting drugs, do not share needles. Seek treatment for drug use. Do not share needles, syringes, cookers, cottons, water, or rinse cups.
The following questions should be asked for every case of viral hepatitis.

**DEMOGRAPHIC INFORMATION**

- **RACE (check all that apply):**
  - Amer Indian or Alaska Native
  - Black or African American
  - White
  - Asian
  - Native Hawaiian or Pacific Islander
  - Other Race, specify: ____________________________________________

- **ETHNICITY:**
  - Hispanic
  - Non-Hispanic
  - Other/Unknown

- **SEX:** Male ☐ Female ☐ Unk ☐

- **DATE OF BIRTH:** M M / D D / Y Y Y Y

- **PLACE OF BIRTH:** ☐ USA ☐ Other: _______________________.

- **DATE OF BIRTH:** M M / D D / Y Y Y Y

**CLINICAL & DIAGNOSTIC DATA**

- **REASON FOR TESTING:** (Check all that apply)
  - Symptoms of acute hepatitis
  - Screening of asymptomatic patient with reported risk factors
  - Screening of asymptomatic patient with no risk factors (e.g., patient requested)
  - Prenatal screening
  - Other: specify:

- **CLINICAL DATA:**

  - **Diagnosis date:** M M / D D / Y Y Y Y

  - **Is patient symptomatic?** ☐ Yes ☐ No ☐ Unk

  - **If yes, onset date:** M M / D D / Y Y Y Y

  - **Was the patient jaundiced?** ☐ ☐ ☐

  - **Was the patient hospitalized for hepatitis?** ☐ ☐ ☐

  - **Due date:** M M / D D / Y Y Y Y

  - **Did the patient die from hepatitis?** ☐ ☐ ☐

  - **Date of Death:** M M / D D / Y Y Y Y

**LIVER ENZYME LEVELS AT TIME OF DIAGNOSIS**

- **ALT (SGPT) Result** ☐ Upper limit normal ☐

- **AST (SGOT) Result** ☐ Upper limit normal ☐

**DIAGNOSIS** (Check all that apply)

- Acute hepatitis A
- Acute hepatitis B
- Chronic HBV infection
- Perinatal HBV infection
- Hepatitis Delat (co- or super-infection)
- Acute hepatitis C
- HCV infection (chronic or resolved)
- Acute hepatitis E
- Acute non-ABC hepatitis

---

*Atlanta, Georgia 30333*

**PUBLIC HEALTH SERVICE**

**HEALTH & HUMAN SERVICES**

**U.S. DEPARTMENT OF**

**VIRAL HEPATITIS CASE REPORT**

**WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES, BUREAU FOR PUBLIC HEALTH, SEPTEMBER 2005**
<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>Unk</th>
</tr>
</thead>
<tbody>
<tr>
<td>During the 2-6 weeks prior to onset of symptoms -</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Was the patient a contact of a person with confirmed or suspected</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A virus infection?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, was the contact (check one)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• household member (non-sexual)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• sex partner</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• child cared for by this patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• babysitter of this patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• playmate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Was the patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• a child or employee in a day care center, nursery, or preschool?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• A household contact of a child or employee in a day care center, nursery or preschool?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes for either of these, was there an identified hepatitis A case</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the child care facility?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Please ask both of the following questions regardless of the patient’s gender.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the 2-6 weeks before symptoms onset how many male sex partners did the patient have?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• female sex partners did the patient have?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the 2-6 weeks before symptom onset</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the patient inject drugs not prescribed by a doctor?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the patient use street drugs but not inject?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did the patient travel outside of the U.S.A. or Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• If yes, where?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the 3 months prior to symptom onset</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Did anyone in the patient’s household travel outside of the U.S.A or Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• If yes, where?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the patient suspected as being part of a common-source outbreak?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, was the outbreak</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foodborne – associated with an infected food handler</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foodborne – NOT associated with an infected food handler</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Specify food item</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waterborne</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Source not identified</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Was the patient employed as a food handler during the TWO WEEKS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior to onset of symptoms or while ill?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VACCINATION HISTORY</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Has the patient ever received the hepatitis A vaccine?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• If yes, how many doses</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• In what year was the last dose received?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Has the patient ever received immune globulin?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• If yes, when was the last dose received?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mo. / Yr.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Patient History – Acute Hepatitis B**

**NETSS ID NO.**

**STATE CASE NO.**

---

**During the 6 weeks – 6 months prior to onset of symptoms**

**Was the patient a contact of a person with confirmed or Suspected acute or chronic hepatitis B virus infection?**

- Yes
- No
- Unk

**If yes, type of contact**

- Sexual
- Household (Non-sexual)
- Other

**Ask both of the following questions regardless of the patient’s gender.**

**In the 6 months before symptom onset how many**

- Male sex partners did the patient have?
- Female sex partners did the patient have?

**Was the patient EVER treated for a sexually transmitted disease?**

- Yes
- No
- Unk

**During the 6 weeks – 6 months prior to onset of symptoms**

- Inject drugs not prescribed by a doctor?
- Use street drugs but not inject?

**During the 6 weeks – 6 months prior to onset of symptoms**

- Undergo hemodialysis?
- Have an accidental stick or puncture with a needle or other object contaminated with blood?
- Receive blood or blood products (transfusion)
  - If yes, when?
- Receive any IV infusions and/or injections in the outpatient setting?
- Have other exposure to someone else’s blood?
  - Specify:

**During the 6 weeks – 6 months prior to onset of symptoms**

- Was the patient employed in a medical or dental field involving direct contact with human blood?
- Was the patient employed as a public safety worker (fire fighter, law enforcement or correctional officer) having direct contact with human blood?
  - Frequent (several times weekly)
  - Infrequent
- Did the patient receive a tattoo?
  - Where was the tattooing performed?
  - Commercial parlor/shop
  - Correctional facility
  - Other

**During the 6 weeks – 6 months prior to onset of symptoms**

- Did the patient have any part of their body pierced (other than ear)?
  - Where was the piercing performed?
    - Check all that apply
  - Commercial parlor/shop
  - Correctional facility
  - Other

- Did the patient have dental work or oral surgery?
- Did the patient have surgery (other than oral surgery)?

**During the 6 weeks – 6 months prior to onset of symptoms**

- Was the patient –
  - Hospitalized?
  - A resident of a long term care facility?
  - Incarcerated for longer than 24 hours?

**During his/her lifetime, was the patient EVER**

- Incarcerated for longer than 6 months
- If yes, what type of facility (check all that apply)
  - Prison
  - Jail
  - Juvenile facility

**Did the patient ever receive hepatitis B vaccine?**

- Yes
- No
- Unk

**If yes, how many shots?**

**In what year was the last shot received?**

**Was the patient tested for antibody to HbsAg (anti-HBs) within 1-2 months after the last dose?**

- Yes
- No
- Unk

**If yes, was the serum anti-HBs \( \geq 10 \text{mIU/ml} \)?**

- Yes
- No
- Unk

(answer “yes” if the laboratory result was reported as “positive” or “reactive”)
**Patient History – Acute Hepatitis C**

**NETSS ID NO. ††††††††††**

**STATE CASE NO. _____________________**

During the **6 weeks – 6 months** prior to onset of symptoms

Was the patient a contact of a person with confirmed or Suspected acute or chronic hepatitis B virus infection?  
**Yes**  **No**  **Unk**

**If yes, type of contact**
- Sexual  
- Household (Non-sexual)  
- Other: ____________________

Ask both of the following questions regardless of the patient’s gender.

In the **6 months** before symptom onset how many
- Male sex partners did the patient have?  
- Female sex partners did the patient have?  
- Inject drugs not prescribed by a doctor?  
- Use street drugs but not inject?

Was the patient **EVER** treated for a sexually transmitted disease?  
- If yes, in what year was the most recent treatment?  

During the **6 weeks – 6 months** prior to onset of symptoms
- Undergo hemodialysis?  
- Have an accidental stick or puncture with a needle or other object contaminated with blood?  
- Receive blood or blood products (transfusion)  
  - If yes, when?  
- Receive any IV infusions and/or injections in the outpatient setting?  
- Have other exposure to someone else’s blood?  
  - Specify: ____________________

During the **6 weeks – 6 months** prior to onset of symptoms

- Was the patient employed in a medical or dental field involving direct contact with human blood?  
- Was the patient employed as a public safety worker (fire fighter, law enforcement or correctional officer) having direct contact with human blood?  
  - Frequent (several times weekly)  
  - Infrequent  
- Did the patient receive a tattoo?  
  - Where was the tattooing performed? (select all that apply)
    - Commercial parlor/shop  
    - Correctional facility  
    - Other  

During the **6 weeks – 6 months** prior to onset of symptoms

- Did the patient have any part of their body pierced (other than ear)?  
  - Where was the piercing performed? (Select all that apply)
    - Commercial parlor/shop  
    - Correctional facility  
    - Other  
- Did the patient have dental work or oral surgery?  
- Did the patient have surgery? (other than oral surgery)  
- Was the patient – **Check all that apply**
  - Hospitalized?  
  - A resident of a long term care facility?  
  - Incarcerated for longer than 24 hours?  

If yes, what type of facility (check all that apply)  
- Prison  
- Jail  
- Juvenile facility

During his/her lifetime, was the patient **EVER**
- Incarcerated for longer than 6 months  
  - If yes  
  - what year was the most recent incarceration?  
  - For how long?  
  - ______ mos.

---

West Virginia Department of Health and Human Resources, Bureau for Public Health, September 2005,   Page 19 of 26
<table>
<thead>
<tr>
<th>RACE OF MOTHER:</th>
<th>ETHNICITY OF MOTHER:</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Amer Indian or Alaska Native</td>
<td>☐ Hispanic</td>
</tr>
<tr>
<td>☐ Black or African American</td>
<td>☐ Non-Hispanic</td>
</tr>
<tr>
<td>☐ White</td>
<td>☐ Other/Unknown</td>
</tr>
<tr>
<td>☐ Unknown</td>
<td></td>
</tr>
<tr>
<td>☐ Asian</td>
<td>☐ Other Race, specify ________________</td>
</tr>
<tr>
<td>☐ Native Hawaiian or Pacific Islander</td>
<td></td>
</tr>
</tbody>
</table>

Was Mother born outside of United States?  
- Yes ☐ No ☐ Unk ☐
  - If yes, on what date did the child receive HBIG?  
    - Y ☐ N ☐ U ☐

Was the Mother confirmed HBsAg positive prior to or at time of delivery?  
- Yes ☐ No ☐ Unk ☐
  - If no, was the mother confirmed HBsAg positive after delivery?  
    - Yes ☐ No ☐ Unk ☐

Date of HbsAg positive test result  
- 0 ☐ 1 ☐ 2 ☐ 3 ☐

How many doses of hepatitis B vaccine did the child receive?  
- Dose 1 ☐ Dose 2 ☐ Dose 3 ☐
- Yes ☐ No ☐ Unk ☐

Did the child receive hepatitis B immune globulin (HBIG)?  
- Yes ☐ No ☐ Unk ☐
  - If yes, on what date did the child receive HBIG?  
    - Y ☐ N ☐ U ☐
CASE DEFINITION FOR REPORTING OF ACUTE VIRAL HEPATITIS

FOR USE BY LOCAL HEALTH DEPARTMENTS TO DETERMINE THE PATIENT’S MOST PROBABLE SOURCE OF INFECTION

<table>
<thead>
<tr>
<th>Patient’s name</th>
<th>Home phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Employed by</td>
<td>Work phone</td>
</tr>
</tbody>
</table>

Reporting physician’s name, address, and phone #

If patient was hospitalized for hepatitis, give name of hospital

Results of liver function test: SGOT (AST) ____ SGPT (ALT) ____ Bilirubin ____

CONTACTS REQUIRING PROPHYLAXIS FOR HEPATITIS B

<table>
<thead>
<tr>
<th>Name</th>
<th>Age</th>
<th>Type of Contact</th>
<th>HBIG</th>
<th>Vaccine</th>
</tr>
</thead>
</table>

2. Name, address and phone # of dentist or oral surgeon.

3. If other surgery performed, name, address and phone # of location

4. If patient is pregnant, give obstetrician’s name, address and phone #

Comments:

Investigator’s Name and Title

Date of Interview
HEPATITIS B VACCINE/ HBIG
TRACKING FORM

1. Name: ____________________________  2. Source Patient: ____________________________
Address: ____________________________
3. Type of Contact: ___ household
   ____ sexual
   ____ needle sharing
Telephone: ____________________________
County: ____________________________

4. Date of Birth: ___/___/____ Age: _____ Race: (circle one) W  B  H  Other Sex: M   F     Weight: ______

5. Risk Factors:
   ____ IDU                      ____ MSM
   ____ Hemophilia               ____ Endemic country
   ____ Housemate of someone    ____ Sex with a person
   with lifelong hep B infection who has hep B
   ____ Multiple sex partners
   ____ Job involves contact with blood
   ____ A patient or someone who
   works in a home for the developmentally disabled

6. A. Hepatitis B Screen
   Date ___/___/____
   *Attach results

   B. Hepatitis Surface Antibody
   Date: ___/___/____
   *Attach results

Medication Administration

7. HBIG
   A. Date: ___/___/____ B. Site: ______________ C. Volume: ______________
   D. Lot number: ______________ E. Manufacturer: _______________
   F. Administered by __________________________

8. Hepatitis B Vaccine
   A. 1st Dose: 1. Date: ___/___/____  2. Site: ______________
   3. Manufacturer: _______________________________
   4. Lot #_____________________________________
   5. Administered by __________________________

   B. 2nd Dose: 1. Date: ___/___/____  2. Site: ______________
   3. Manufacturer: _______________________________
   4. Lot #_____________________________________
   5. Administered by __________________________

   C. 3rd Dose: 1. Date: ___/___/____  2. Site: ______________
   3. Manufacturer: _______________________________
   4. Lot #_____________________________________
   5. Administered by __________________________

Submit form to:
HIV/AIDS/STD Program
West Virginia Bureau for Public Health
350 Capitol Street, Room 125
Charleston, WV 25301-3715
Telephone: 1-800-642-8244 or (304)558-2195
Fax: 1-304-558-6478

Please refer to back of form for directions.
West Virginia Department of Health and Human Resources, Bureau for Public Health, September 2005
1. Name of contact
2. Name of contact of source patient.
3. Check all that apply.
4. Enter date of birth, age, race sex, weight (in pounds and convert to kilograms).
5. Risk factors (check all that apply)
6. A. Enter date of hepatitis B screen. Attach results of testing.
   B. Enter date of hepatitis B surface antibody screen after completion of 3 dose series of hepatitis vaccine. Attach results of testing.
7. HBIG
   A. Enter date administered.
   B. Enter site of injection (if over 2 ml administered in upper outer quadrant of buttock).
   C. Enter volume administered.
   D. Enter lot number of HBIG administered.
   E. Enter manufacturer of HBIG.
   F. Print the name of the person administering the HBIG.
8. Hepatitis B Vaccine
   A. 1st dose
      1. Enter date administered.
      2. Enter the site of injection.
      3. Enter the name of manufacturer.
      4. Enter the lot number of the vaccine.
      5. Print the name of the person administering the hepatitis B vaccine
   B. 2nd dose
      1. Enter date administered.
      2. Enter the site of injection.
      3. Enter the name of manufacturer.
      4. Enter the lot number of the vaccine.
      5. Print the name of the person administering the hepatitis B vaccine
   C. 3rd dose
      1. Enter date administered.
      2. Enter the site of injection.
      3. Enter the name of manufacturer.
      4. Enter the lot number of the vaccine.
      5. Print the name of the person administering the hepatitis B vaccine

*After administering each dose of hepatitis B vaccine or HBIG, copy the tracking form and forward it to the address listed at the bottom of first page.
Hepatitis B Case Ascertainment Worksheet

Case Definition for Acute Hepatitis B

Clinical Description
An acute illness with: a) discrete onset of symptoms, and b) jaundice or elevated serum aminotransferase levels.

Laboratory Criteria for Diagnosis

- IgM antibody to hepatitis B core antigen (anti-HBc) positive or hepatitis B surface antigen (HbsAg) positive.
- IgM anti-HAV negative (if done).

Case Classification

Confirmed: a case that meets the clinical case definition and is laboratory confirmed.

Comments

Persons who have chronic hepatitis or persons identified as HBsAg positive should not be reported as having acute viral hepatitis unless they have evidence of an acute illness compatible with viral hepatitis (with the exception of perinatal hepatitis B infection).

Guidelines for investigating hepatitis B

Local health department (LHD) receives a lab report with a HBsAg and/or HbcAb IgM positive marker.

1. Conduct an internal record search – has patient been reported before?
   - Yes
     - If chronic case (Hepatitis B surface antigen [HBsAg] positive, total anti-HBc positive [if done] and IgM anti-HBc negative, OR HBsAg positive two times at least 6 months apart), ensure education was originally provided and close case
     - If lab is a follow-up to an acute case – add to WVEDSS and forward a hard copy to State Hepatitis B Epidemiologist
   - No
     - Begin investigation to determine if this is an acute hepatitis B case

2. Call the provider to collect additional patient information
   - d. Confirm patient’s demographics. e.g. complete name, address, phone number, date of birth, etc.
   - e. Reason for testing?
   - f. Is the patient symptomatic? e.g. jaundice, nausea, vomiting, fatigue, dark urine, clay colored stool, etc
   - g. Date of onset of illness?
   - h. Is the patient pregnant?
     - Yes
       - Ask when is the EDD (estimated date of delivery)
       - Notify the Perinatal Hepatitis B Coordinator at the Immunization Program immediately (1-800-642-3634).
     - No
   - i. Are there any other lab tests? e.g. hepatitis A & C, liver enzymes, bilirubin
   - j. Does the patient have a history of IV drug abuse and or alcohol abuse?
   - k. Does the patient have a hepatitis B vaccine history?
     - Yes
       - dates of vaccination
       - number of doses received
       - manufacture name & vaccine lot number
   - l. Did the physician notify the patient of the positive lab report?
     - Yes
       - Work with the provider to identify contacts
       - Provide necessary public health action
     - No
3. Conduct an investigation using the CDC Viral Hepatitis Case Report form to identify any risk factors. (CDC form is available in the Hepatitis B protocol and on the IDEP website http://www.wvdhhr.org/IDEP/PDFs/IDEP/CDC_hepatitis.pdf)

   a. Investigate 6 weeks to 6 months prior to illness onset
      i. Did the patient have multiple sex partners?
      ii. How many female sex partners did the patient have?
      iii. How many male sex partners did the patient have?
      iv. Did the patient have a history of STDs?
      v. Was the patient an injecting drug user (sharing needles and/or “works”)?
      vi. Was the baby born to a HBsAg positive mother?
      vii. Did the patient have any household members or sexual contacts that could have been exposed?
      viii. Did the patient’s employment expose him to human blood?
      ix. Was the patient ever incarcerated?

4. Conduct contact tracing to identify the following contacts and provide the necessary public health interventions:
   a. Sexual contacts
      Was the last sexual contact(s) within 14 days and is the vaccine immune status unknown? If yes, ensure that:
      - a blood sample from the contact(s) is submitted to WV OLS for hepatitis B screen.
      - the hepatitis B immunoglobulin (HBIG) and the first dose of hepatitis B vaccine is administered to the contact(s).
        - If hepatitis serologies are positive, stop vaccination series and refer the patient for medical care. If serologies are negative, complete the full immunization series.
      - the hepatitis B tracking form is completed and it is submitted to the HIV/AIDS/STD Program.

   b. Needle sharing contacts
      Was the last needle sharing contact(s) within 7 days and is the vaccine immune status unknown? If yes, ensure that:
      - a blood sample from contact(s) is submitted to WV OLS for hepatitis B screen.
      - the hepatitis B immunoglobulin (HBIG) and the first dose of hepatitis B vaccine is administered to the contact(s).
        - If hepatitis serologies are positive, stop vaccination series and refer the patient for medical care. If serologies are negative, complete the full immunization series.
        - HBIG must be administered within a week after the last needle sharing event with the source patient.
      - the hepatitis B tracking form is completed and it is submitted to the HIV/AIDS/STD Program.

   c. Household contacts
      Was the last household contact(s) within 14 days and the vaccine immune status unknown? If yes, ensure that:
      - a blood sample from contact(s) is submitted to WV OLS for hepatitis B screen.
      - the hepatitis B immunoglobulin (HBIG) and the first dose of hepatitis B vaccine is administered to the contact(s).
        - If hepatitis serologies are positive, stop vaccination series and refer the patient for medical care. If serologies are negative, complete the full immunization series
      - the hepatitis B tracking form is completed and it is submitted to the HIV/AIDS/STD Program.

   If prophylaxis is needed contact the State Hepatitis B Epidemiologist or your Disease Intervention Specialist (DIS) 1-800-642-8244.

5. Refer for medical evaluation
   m. Persons with acute hepatitis B should be evaluated for development of chronic infection
   n. Detection of HBsAg >6 months after illness onset indicates the presence of chronic infection.
   o. Evaluate for chronic liver disease, eligibility for treatment.

6. Report
   a. Enter data into WVEDSS including labs and submit for State Review. Until WVEDSS is functional, send a paper copy and all appropriate laboratory studies to the West Virginia HIV/AIDS/STD program, as well as submitting it electronically.
SEROLOGY LABORATORY
Hepatitis Requisition Form

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Employee</th>
<th>Indigent</th>
<th>Patient</th>
<th>Reason for request</th>
<th>Date of Birth:</th>
<th>Sex:</th>
<th>Date of Collection:</th>
<th>RACE</th>
<th>ETHNICITY</th>
<th>RISK GROUPS (Check as many as apply)</th>
<th>SPECIMEN UNSATISFACTORY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Contact Investigation</td>
<td></td>
<td></td>
<td></td>
<td>White</td>
<td>Hispanic Latino</td>
<td>Previous diagnosed positive</td>
<td>FOR THE FOLLOWING REASONS:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Employment Requirement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hispanic Non Latino</td>
<td>Injecting drug user with current or prior history</td>
<td>Insufficient volume</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Non - Hispanic</td>
<td>Hemophilia</td>
<td>Hemolyzed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unknown</td>
<td>Needle stick/blood splash</td>
<td>Lipemic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Household contact</td>
<td>Prostitute</td>
<td>Broken</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sexual Contact with</td>
<td>Multiple transfusion &gt; 5 units</td>
<td>No name on tube</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>Injecting drug user</td>
<td>Other</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>Known infected person</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>Homosexual/ Bisexual</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>Multiple partners</td>
<td></td>
</tr>
</tbody>
</table>

TESTS REQUESTED

- Hepatitis B virus Screen (includes HBV sAg and cAb) The viral antigen is sAg, cAb is the most long lasting antibody.
- Hepatitis B virus Post Vaccine (HBV anti-sAg) This is the only antibody present after vaccine.
- Hepatitis B virus OCME (HBV sAg only) Cadaver blood
- Other: 
- Hepatitis A virus (HAV - IgM ) Acute phase only
- Hepatitis C virus (total antibody) Does not distinguish acute/convalescent stages.

Facility: ____________________________

Person receiving results: ____________________________

Address: ____________________________

Phone Number: _______ - _______ FAX: _______ - _______